Hugo Thomas Torquil Mackenzie-Smith
Directeur/Membre du Conseil chez Ellenborough Park Hotel
Profil
Hugo Thomas Torquil Mackenzie-Smith has held director positions at Immodulon Therapeutics Ltd.
since 2009 and at Ellenborough Park Hotel since 2012.
Postes actifs de Hugo Thomas Torquil Mackenzie-Smith
| Sociétés | Poste | Début |
|---|---|---|
Ellenborough Park Hotel
 Ellenborough Park Hotel Hotels/Resorts/Cruise linesConsumer Services Part of Shetland Business Ltd., Ellenborough Park Hotel is a luxury 5-star hotel located in Cheltenham, UK. In addition to its luxurious accommodations, Ellenborough Park Hotel also offers exciting activities such as husky driving and archery to showcase the best of the Cotswolds. Founded in 2008, the hotel offers a uniquely charming corporate meeting event venue, spa, and a range of dining options including alfresco dining. | Directeur/Membre du Conseil | 17/01/2012 |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Directeur/Membre du Conseil | 01/01/2009 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |
Ellenborough Park Hotel
Ellenborough Park Hotel Hotels/Resorts/Cruise linesConsumer Services Part of Shetland Business Ltd., Ellenborough Park Hotel is a luxury 5-star hotel located in Cheltenham, UK. In addition to its luxurious accommodations, Ellenborough Park Hotel also offers exciting activities such as husky driving and archery to showcase the best of the Cotswolds. Founded in 2008, the hotel offers a uniquely charming corporate meeting event venue, spa, and a range of dining options including alfresco dining. | Consumer Services |
